Dianthus Therapeutics, Inc. (DNTH)
$
20.06
-0.55 (-2.74%)
Key metrics
Financial statements
Free cash flow per share
-2.1820
Market cap
586.9 Million
Price to sales ratio
89.9632
Debt to equity
0.0042
Current ratio
15.9853
Income quality
0.7763
Average inventory
0
ROE
-0.2926
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for individuals affected by severe autoimmune and inflammatory diseases. The operating income ratio is -16.34 indicating the company's operational profitability margin. The EBITDA ratio is -16.27 highlighting the company's operational efficiency. The company reported selling, general, and administrative expenses of $24,994,000.00 indicating its operational overhead costs. The company's stock is identified with the symbol 'DNTH' in the market. Moreover, the diluted EPS is -$2.55 accounting for potential share dilution. Currently, the company is developing DNTH103, which is undergoing phase 1 clinical trials for conditions including generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Incorporated in 2015, Dianthus Therapeutics is based in New York, New York, and plays a vital role in the biotechnology sector. The stock is affordable at $20.61 suitable for budget-conscious investors. It has a low average trading volume of 301,177.00 indicating lower market activity. With a market capitalization of $645,129,580.00 the company is classified as a small-cap player. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth within its field. The strategic focus on developing groundbreaking therapies for autoimmune and inflammatory diseases positions Dianthus Therapeutics as a promising candidate for investors seeking exposure to the biotechnology sector.
Is Dianthus Therapeutics, Inc. (DNTH) a good investment?
Investing in Dianthus Therapeutics, Inc. (DNTH) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Dianthus Therapeutics, Inc. (DNTH)'s stock forecast?
Analysts predict Dianthus Therapeutics, Inc. stock to fluctuate between $13.37 (low) and $32.27 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Dianthus Therapeutics, Inc.'s market capitalization?
As of 2025-07-11, Dianthus Therapeutics, Inc.'s market cap is $645,129,580, based on 32,159,999 outstanding shares.
How does Dianthus Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Dianthus Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Dianthus Therapeutics, Inc. (DNTH) stock?
To buy Dianthus Therapeutics, Inc. (DNTH) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for DNTH. Place an order (Market, Limit, etc.).
What is the best time to invest in Dianthus Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Dianthus Therapeutics, Inc. stock ever split?
Dianthus Therapeutics, Inc.'s last stock split was 1:16 on 2023-09-12.
How did Dianthus Therapeutics, Inc. perform in the last earnings report?
Revenue: $6,235,000 | EPS: -$2.55 | Growth: -69.82%.
Where can I find Dianthus Therapeutics, Inc.'s investor relations reports?
Visit https://dianthustx.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Dianthus Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Dianthus Therapeutics, Inc. stock?
All-time high: $33.77 (2024-03-22) | All-time low: $6.58 (2023-12-19).
What are the key trends affecting Dianthus Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
a month ago
NEW YORK and WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the Company's participation in the Jefferies Global Healthcare Conference. Marino Garcia, Chief Executive Officer, will participate in a fireside chat on Thursday, June 5, 2025 at 9:55 a.m. EDT in New York City and will host one-on-one meetings with investors.
globenewswire.com
2 months ago
Dr. Read brings >30 years of leadership and scientific expertise in the biopharmaceutical industry Previously served as CEO and Founder of Mariana Oncology until its acquisition by Novartis in 2024 and CSO of Ra Pharma until its acquisition by UCB in 2020 NEW YORK and WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the appointment of Simon Read, Ph.D.
zacks.com
2 months ago
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to loss of $0.54 per share a year ago.
globenewswire.com
2 months ago
Completed enrollment in Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) Top-line MaGic results anticipated in September 2025 to be the first of three catalysts for the DNTH103 neuromuscular franchise by YE'26 Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ongoing; interim responder analysis anticipated in 2H'26 Phase 2 MoMeNtum trial of DNTH103 in Multifocal Motor Neuropathy (MMN) ongoing; top-line results anticipated in 2H'26 $331.5 million of cash provides runway into 2H'27 NEW YORK and WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the first quarter ending March 31, 2025, and provided an update on recent business achievements.
globenewswire.com
2 months ago
MaGic trial exceeded enrollment target of 60 patients Top-line results anticipated this September will be the first of three DNTH103 catalysts by YE'26 Building a neuromuscular franchise with DNTH103 in gMG, CIDP and MMN with a potential best-in-class, potent classical pathway inhibitor intended as a self-administered autoinjector dosed once every two weeks NEW YORK and WALTHAM, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced completion of enrollment in the Phase 2 MaGic trial of DNTH103 in patients with generalized Myasthenia Gravis (gMG).
globenewswire.com
2 months ago
NEW YORK and WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation at two upcoming investor events.
zacks.com
3 months ago
Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
zacks.com
4 months ago
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.71 per share a year ago.
globenewswire.com
4 months ago
Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H'25 Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ongoing; interim responder analysis anticipated in 2H'26 Phase 2 MoMeNtum trial of DNTH103 in Multifocal Motor Neuropathy (MMN) ongoing; top-line results anticipated in 2H'26 $357.0 million of cash provides runway into 2H'27 NEW YORK and WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the fourth quarter and full year ending December 31, 2024 and provided an update on recent business achievements.
globenewswire.com
4 months ago
Mr. King launched the first approved biologic and C5 complement inhibitor into the Myasthenia Gravis market and helped set the foundation for the multi-billion dollar C5 franchise of Alexion
See all news
